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Edited by Veli-Pekka LehtoAbstract Neostatin-7, with an anti-angiogenic potential, is gen-
erated from the proteolytic action of matrix metalloproteinase-7
on collagen XVIII. We previously reported that neostatin-7
inhibited angiogenesis in vitro and in vivo. Here we demonstrate
that neostatin-7/collagen XVIII may possess anti-lymphangio-
genic activities by: (1) corneal micropellet implantation of neost-
atin-7 reduced bFGF-induced corneal lymphangiogenesis; (2)
neostatin-7 bound to VEGF receptor-3 in vitro; and (3) enhanced
corneal lymphangiogenesis and VEGF-C expression in collagen
XVIII knockout mice in a corneal wounding model. Understand-
ing the mechanism of neostatin-7/collagen XVIII on corneal lym-
phangiogenesis may provide therapeutic interventions to treat
lymphangiogenesis-related disorders, such as lymphedema,
transplantation rejection and cancers.
Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Lymphangiogenesis is deﬁned as proliferation of new lymph-
atics by sprouting from veins or de novo from lymphangio-
blasts [1]. The lymphatic networks play an important
physiological role in the regulation of tissue ﬂuid homeostasis
in immune responses to pathogens and fat absorption [2]. In
pathological disorders, lymphangiogenesis frequently occurs
in corneal wound healing, the inﬂammatory setting of corneal
transplantation, and the spreading of malignant tumors [3].
In the normal state, the cornea is avascular. Corneal angio-
genesis and lymphangiogenesis are mediated by the growth
factors of the VEGF family. VEGF-A induces corneal vascu-
logenesis and angiogenesis by binding to VEGF receptor-1
(VEGFR1/ﬂt-1) and -2 (VEGFR2/ﬂk-1/KDR). VEGF-C and
VEGF-D, lymphangiogenic factors, both bind to their high-
aﬃnity receptors, VEGFR2 and VEGFR3. Recently, soluble
VEGFR1 in corneal epithelium was shown to mediate primar-
ily inhibitory or decoy functions for corneal angiogenesis [4].
Similarly, VEGFR3 expression in corneal epithelium acts as
a sink for VEGF-C and -D [5].
Vascular endothelial growth factor receptor (VEGFR)-3 has
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vessels, and mutations of VEGFR-3 may cause primary
lymphedema [6]. Additionally, inhibition of VEGFR-3 signal-
ing by soluble VEGFR-3 or a neutralizing antibody lead to
lymphatic vessel regression in a transgenic mouse model
[3,7–9]. VEGF-C is a known ligand of VEGFR-3 and has been
shown to be able to induce the growth of new lymphatic vessels
in vivo. VEGF-C belongs to the larger VEGF family of growth
factors and is required for the initial sprouting and migration
of lymphatic endothelial cells from embryonic veins. Mice
lacking VEGF-C die prenatally [10,11].
Collagen XVIII has been shown to be cleaved by several
proteases, including MMP-7, MMP-14, and Cathepsin L, to
generate endostatin-containing fragments and endostatin [12–
14]. MMP-7 cleaves NC-1 fragments of collagen XVIII to gen-
erate neostatin-7, which contains an additional 60 amino acids
at the N-terminal of endostatin. MMP-14 cleaves NC-1 frag-
ments to generate neostatin-14, which contains 14 additional
amino acids at the N-terminal of endostatin.
Endostatin, an anti-angiogenic factor, is a 20 kDa proteo-
lytic fragment of collagen XVIII [15]. This fragment has been
shown to inhibit bFGF- and VEGF-induced vascular endothe-
lial cell migration and proliferation in vitro, and to diminish
tumor progression in mice in vivo [16,17]. Similarly, endo-
statin-containing fragments also possess anti-angiogenic prop-
erties. The mechanisms of endostatin in anti-angiogenic and
anti-tumor growth have been intensively investigated. For
example, Kim et al. showed that endostatin binds directly to
VEGF receptor 2 but not to VEGF. This speciﬁc binding
blocked VEGF-induced tyrosyl phosphorylation of VEGFR2,
MAP kinase, and focal adhesion kinase in human umbilical
vein endothelial cells [18].
Recently, Teodoro et al. demonstrated a genetic and bio-
chemical linkage between the p53 tumor suppressor pathway
and the synthesis of anti-angiogenic collagen XVIII fragments
[19]. Based on our previous study of neostatin-7 inhibiting
bFGF-induced corneal neovascularization [5,16,20], we fur-
ther investigated the eﬀects of neostatin-7on bFGF-induced
corneal lymphangiogenesis in vivo and its interaction with
VEGFR3 in vitro. Our data was in agreement with Brideau
et al. who showed diminished-lymphangiogenesis in carcino-
gen-induced skin tumors in transgenic J4 mice overexpressing
endostatin in their keratinocytes [21].
In this report, we showed an involvement of collagen XVIII/
neostatin-7 in corneal lymphangiogenesis through: (1) en-
hanced corneal lymphangiogenesis and VEGF-C expression
in collagen XVIII knockout mice after corneal keratectomy;
(2) inhibited bFGF-induced corneal lymphangiogenesis in vivo
with recombinant neostatin-7 treatment; and (3) binding of re-
combinant neostatin-7 to VEGFR3-Fc in vitro. These ﬁndingsEuropean Biochemical Societies.
2516 T. Kojima et al. / FEBS Letters 582 (2008) 2515–2520provide a basis for further understanding the mechanism of
neostatin-7 in corneal lymphangiogenesis. In addition, this
information may lead to future therapeutic interventions for
the treatment of lymphangiogenesis-related disorders, such as
transplantation rejection and cancer metastasis.2. Materials and methods
2.1. Animals
Col18a1/mice were generously provided by Drs. B. Olsen and N.
Fukai (Department of Oral and Developmental Biology, Harvard
School of Dental Medicine, Boston, Massachusetts). This study was
conducted in accordance with the ARVO Statement for the Use of
Animals in Ophthalmic and Vision Research and has been approved
by the Animal Care and Use Committee at the University of Illinois
at Chicago.
2.2. Generation of recombinant GST-neostatin-7
Mouse collagen XVIII cDNAs containing neostatin-7 were ampli-
ﬁed through polymerase chain reactions (PCR) from the NC1 frag-
ment and subcloned into the pGEX vector (pharmacia). The primers
used were 5 0 XVIII neostatin-7 CCTGAGGCACGGAATTCCAGG-
TGGCTGCTTTCC and 3 0 XVIII endostatin CTGCCACCCTAGC-
TGGCGGCCGCCTATTTGGAGAAAGAGG. These constructs
were transformed intoEscherichia coli (BL21DE3, Novagen, Madison,
WI), and a single colony was isolated for each construct. The bacteria
were grown to semi-log phase isopropyl thiogalactopyanoside (Gibco
BRL, Gaithersburg, MD), at which point they were induced with
0.3 mM of IPTG to produce GST-neostatin-7 fusion protein. The bac-
teria were then lysed with lysis buﬀer (RIPA containing lysozyme), and
the protein was isolated using glutathione sepharose 4B beads (Phar-
macia). GST-endostatin-containing fragments were eluted with
10 mM glutathione (in 50 mM Tris–HCl, pH 8.0) and dialyzed against
PBS. The purity of the GST-fusion protein was determined by Coo-
massie Brilliant Blue staining.
2.3. Corneal pocket assay with bFGF in the presence of GST or GST-
endostatin-containing fragments
A corneal micropocket assay was performed as described previously
[22,23]. Brieﬂy, wild-type mice (C57BL/6) were anesthetized by intra-
peritoneal injection of ketamine and xylazine. Corneal micropockets
were created using a modiﬁed von Graefe knife. Uniformly sized hy-
dron pellets containing 80 ng of human bFGF (R&D Systems, Minne-Fig. 1. Puriﬁcation of GST-neostatin-7 from E. coli. (A) Schematic diagram
neostatin-7 were isolated, subjected to SDS gel electrophoresis, and stained w
2 = GST; lane 3 = GST-neostatin-7.apolis, MN, USA) with either 500 ng of GST or GST-neostatin-7 and
40 lg of sucrose aluminum sulfate were implanted into corneal pock-
ets. The eyes were then examined and photographed on day 7 with
post-pellet implantation by slit lamp microscopy (Nikon, Tokyo, Ja-
pan). The neovascular area was calculated using the NIH ImageJ pro-
gram. Corneas were whole mount immunostained with anti-LYVE-1
and CD31 antibodies and then analyzed by confocal microscopy.
2.4. Mouse corneal keratectomy model
The whole mount immunohistochemistry staining was used to assay
corneal lymphangiogenesis. Trephine (1.5 mm) was used to make an
incision to the mid stroma. The central part of the corneal stroma
was dissected 7 days post-keratectomy wounding. Corneal lymphatic
and vascularized vessels were immunostained with anti-LYVE-1 and
CD31 antibodies, and were examined with confocal microscopy.
2.5. Whole mount immunohistochemistry of corneal lymphangiogenesis
Whole corneas, treated with bFGF pellets or keratectomy, were ﬁxed
in a 4:1 mixture of 100% methanol and dimethyl sulfoxide for 2 h at
room temperature and then in 100% methanol at 20 C. The corneas
were treated further with 70%, 50%, and 30% methanol (in phosphate-
buﬀered saline) for 30 min each. The corneas were then blocked with
1% bovine serum albumin in PBS for 30 min, immunostained with
anti-LYVE-1 and CD31 antibodies, and incubated overnight at 4 C.
After washing with PBS, the secondary antibodies, FITC-conjugated
donkey anti-rabbit and Cy5-conjugated donkey anti-rat IgG (Jackson
ImmunoResearch, West Grove, PA), were incubated for 4 h. After
immunostaining, the corneas were cut using four radial incisions from
the peripheral rim, ﬂattened on the glass slide, and subsequently exam-
ined by confocal microscopy (Leica, Heidelberg, Germany).3. Results
3.1. GST-neostatin-7 reduced bFGF-induced corneal
angiogenesis and lymphangiogenesis
A schematic diagramof typeXVIII collagen, NC1, and neost-
atin-7 is depicted in Fig. 1A. To isolate suﬃcient amounts of
GST-neostatin-7 for neostatin-7 and VEGF receptor binding
assays in vitro and corneal implantation in vivo, GST and
GST-neostatin-7 constructs were used to generate proteins from
E. coli. The Coomassie Brilliant Blue staining bands in Fig. 1B
corresponds to the molecular weight of GST (26 kDa) and
GST-neostatin-7 (54 kDa).of type XVIII collagen, NC1, and neostatin-7. (B) GST and GST-
ith Coomassie Brilliant Blue. Lane 1 = molecular weight markers; lane
Fig. 3. GST-neostatin-7 bound to recombinant VEGFR3-Fc in vitro.
Puriﬁed GST and GST-neostatin-7 from E. coli were mixed with or
without recombinant VEGFR3-Fc in the RIPA buﬀer. GST-neostatin-
7 associated VEGFR3-Fc was pulled down by glutathione beads and
assayed by Western blot using an anti-VEGFR3 antibody. GST-
neostatin-7 associated with recombinant VEGFR3-Fc (lane 4), and
GST that did not associate with VEGFR3-Fc served as a negative
control (lane 3). Recombinant VEGFR3-Fc served as a positive
control (lane 5). Lane 1 = GST only and lane 2 = GST-neostatin-7
only.
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7-naked DNA into mouse corneas reduced bFGF-induced cor-
neal neovascularization when compared to vector-injected
control corneas [16]. To address whether or not co-implanta-
tion of neostatin-7 proteins and bFGF in the cornea can re-
duce bFGF-induced cornea neovascularization, bFGF
(80 ng/pellet) plus GST (500 ng/pellet), bFGF (80 ng/pellet),
and GST-neostatin-7 (500 ng/pellet) were implanted into
mouse corneas, and corneal neovascularization images were
taken by slit lamp 7 days post-implantation (Fig. 2A and E).
bFGF-induced corneal neovascularization was signiﬁcantly re-
duced in corneas that were implanted with pellets containing
GST-neostatin-7 (Fig. 2E) relative to that in bFGF and GST
implanted cornea controls (Fig. 2A). The NIH ImageJ digi-
tized neovascularized areas from these two types of implanted
corneas were calculated and compared, as shown in Fig. 2I
(P < 0.05) (see Fig. 3).
Corneal lymphangiogenesis and neovascularization were
visualized on day 7, after either bFGF plus GST or bFGF plus
GST-neostatin-7 implantation. Diminished corneal lymphatic
vessels were observed in the GST-neostatin-7 plus bFGF im-
planted cornea (Fig. 2F) relative to that in the GST plus bFGF
implanted cornea (Fig. 2B). The areas of cornea lymphangio-
genesis in the GST-neostatin-7 plus bFGF were smaller than
those of the GST plus bFGF implanted corneas (Fig. 2J).
3.2. GST-neostatin-7 binds to recombinant VEGFR3-Fc in vitro
Kubo et al. showed that blockage of VEGF receptor 3 sig-
naling inhibited bFGF-induced corneal lymphangiogenesis
[24]. To determine if neostatin-7 is associated with VEGFR3Fig. 2. GST-neostatin-7 reduced bFGF-induced corneal hem- and lymphangi
either GST (500 ng/pellet) (A) or GST-neostatin-7 protein (500 ng/pellet) (B).
7 days after pellet implantation. The pellet containing GST-neostatin-7
lymphangiogenesis was visualized by whole mount immunohistochemical sta
Enhanced corneal lymphangiogenesis was visualized in GST plus bFGF impl
observed in GST-neostatin-7 plus bFGF implanted corneas (F). Overlay imag
(H), respectively. Quantiﬁcation of lymphatic vessels showed a reduction in
* represents P < 0.05.in vitro, we performed an in vitro pull-down assay and subse-
quent Western blot analysis. We detected GST-neostatin-7ogenesis. Mouse corneas were implanted with bFGF (80 ng/pellet) plus
Corneal neovascularization images were taken by slit lamp microscopy
signiﬁcantly reduced bFGF-induced neovascularization (I). Corneal
ining using anti-LYVE-1 antibody on day 7 after pellet implantation.
anted corneas (B); however, diminished corneal lymphatic vessels were
es of corneal angiogenesis and lymphangiogenesis are shown in (D) and
corneal lymphatic vessels in GST-neostatin-7 implanted cornea (J).
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lane 4), but GST did not associate with VEGFR3-Fc as a neg-
ative control (Fig. 4, lane 3).
3.3. Enhanced corneal lymphangiogenesis in col18a1/ mouse
cornea after keratectomy wounds
To address whether or not collagen XVIII (the parent mol-
ecule of neostatin-7) plays a role in the regulation of corneal
lymphangiogenesis, corneas of WT and col18a1/ mice were
wounded by 1.5 mm keratectomy. Enhanced corneal lympha-
tic and vascular vessels were visualized in the col18a1/
mouse corneas (Fig. 4B and C), and few to no corneal lympha-
tic vessels were detected in WT mouse corneas 7 days after cor-
neal keratectomy (Fig. 4F and G). The areas of lymphatic
vessels in keratectomy-treated col18a1/ corneas were three
times larger than those of wild-type keratectomy-treated
mouse corneas (Fig. 4I). Additionally, enhanced corneal
VEGF-C expression was detected in the keratectomy-treated
cornea in col18a1/ mice relative to that in wild-type mice
(Fig. 5).4. Discussion
Neostatin-7, a 28 kDa fragment, is generated by MMP-7
cleavage of type XVIII collagen. Neostatin-7 is one of several
naturally occurring endostatin-spanning fragments identiﬁed
in human blood [13,25]. Type XVIII collagen is a basement
membrane protein and is expressed in ocular basement mem-Fig. 4. Enhanced corneal lymphangiogenesis in col18a1/ mouse corne
keratectomy in WT and col18a1/mice. A slit lamp photograph of col18a1
obvious corneal neovascularization. Mouse corneas were whole mount immu
confocal microscopy. Little or no corneal lymphatic vessels were visualized
corneal lymphatic vessels were visualized in the col18a1/ mouse corneas (
shown in (D) and (H), respectively. Quantiﬁcation of lymphatic vessel areas
WT mouse corneas (I). * represents P < 0.05.branes, including the vascular endothelial membrane and Bow-
mans membrane of the cornea [26,27]. The location of
collagen XVIII and its proteolytic degraded fragments in cor-
neal tissues may imply that it plays a role in corneal angiogen-
esis and lymphangiogenesis.
Endostatin and neostatin-7 are generated by diﬀerent prote-
ase cleavages of collagen XVIII. It has been shown that endo-
statin is generated by the cleavage of collagen XVIII by
Cathepsin B, D, and L [12,14]. Endostatin inhibits cell migra-
tion and cell proliferation, decreases tumor size, and enhances
vascular endothelial cell apoptosis in vitro and in vivo [21].
The mechanisms involved in the eﬀect of endostatin on vascu-
lar endothelial cells have been extensively investigated, and
several endostatin-associated molecules have been isolated
and characterized, including matrix metalloproteinase-2, L-
selectin, integrin avb3, VEGF receptor, tropomyosin, glypican,
laminin, and heparin-like glycosaminoglycans [28,29]. Such
data suggests that endostatin binds to these cellular counter-
parts, and this binding may facilitate the inhibitory function
of endostatin in vascular endothelial cell proliferation.
The anti-angiogenic properties of endostatin and neostatin-7
have been revealed by the knockout of the parent molecule col-
lagen XVIII gene in mice. The potency diﬀerence between the
eﬀects of neostatin-7 and endostatin on corneal lymphangio-
genesis remains to be determined. A delayed regression of
blood vessels in the vitreous along the surface of the retina
after birth as well as an abnormal outgrowth of retinal vessels
in col18a1/ mice have been shown [30]. Loss of collagen
XVIII in mice has shown increased angiogenic response in aor-as after keratectomy wounding. Corneas were wounded by 1.5 mm
/mice (A) and WT mice (E) on day 7 after keratectomy displayed no
nostained with anti-LYVE-1 and CD31 antibodies, and visualized by
in WT mouse corneas after keratectomy (F), but keratectomy-induced
B). Overlay images of corneal angiogenesis and lymphangiogenesis are
were compared between anti-LYVE immunostained col18a1/ and
Fig. 5. Enhanced VEGF-C production in col18a1/ mouse after corneal keratectomy. VEGF-C expression increased in the limbal area with little
expression in the central cornea in col18a1/ mice. The level of VEGF-C expression in keratectomy-treated col18a1/ mouse corneas was
approximately three times that of wild-type mouse corneas.
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meability in atherosclerosis [31,32]. Investigations of injury-in-
duced corneal lymphangiogenesis in collagen XVIII knockout
mice imply that collagen knockout mice may be deﬁcient in
anti-lymphangiogenic molecules (i.e. proteolytic fragments of
collagen XVIII such as endostatin and neostatin-7).
In the cornea, the balance between lymphangiogenic, angio-
genic, and anti-angiogenic factors controls the avascular milieu
of the cornea and is governed by many variable factors. Stim-
uli from injuries generate various responses aimed to produce
factors and prevent hemangiogenesis and lymphangiogenesis.
Our previously published data demonstrated an up-regulation
of MMP-7 in wild-type animal wounding models and an in-
creased vascular response in MMP-7-deﬁcient littermates
[33]. It is our hypothesis that MMP-7-derived, endostatin-con-
taining fragments (including neostatin-7) may be among fac-
tors that prevent new vascular and lymphatic vessel
formation after wounding.
Lymphangiogenesis is an essential component in many phys-
iologic and pathologic processes such as development, tissue
growth, wound repair, and cancer metastasis. The onset of cor-
neal lymphangiogenesis is regulated by the balance between
pro-lymphangiogenic and anti-lymphangiogenic factors. cor-
neal lymphangiogenesis may require not only the up-regula-
tion of pro-lymphangiogenic factors, but also the down-
regulation of anti-lymphangiogenic factors. Use of the cornea
as a model has allowed the study of lymphangiogenic and anti-
lymphangiogenic molecules in vivo. Although the involvement
of neostatin-7 is not proved in the corneal model of the en-
hanced eﬀect of injury-induced corneal lymphangiogenesis in
collagen XVIII knockout mice, our injury-induced corneal
lymphangiogenesis model in collagen XVIII knockout mice
showed that collagen XVIII or one of its degradation products
is involved in regulating corneal lymphangiogenesis during
wound healing. Our data also showed that enhanced corneal
lymphangiogenesis and VEGF-C expression were present in
keratectomy-treated collagen XVIII knockout mice.
In addition, reduced bFGF-induced corneal lymphangio-
genesis by neostatin-7 was demonstrated by administrationof recombinant GST-neostatin-7 and bFGF in corneal micro-
pellet implantation. These results conﬁrm and expand upon
previous ﬁndings in mouse skin [21]. In addition, the novel
observation of the neostatin-7 binding with VEGFR3 in vitro
may provide a role for neostatin-7 in the regulation of corneal
lymphangiogenesis. The signiﬁcance of this ﬁnding may pro-
vide new target molecules for the treatment of corneal and
ocular angiogenic- and lymphangiogenic-related disorders, as
well as neoplasm, wounds, and infections.Acknowledgements: We thank Drs. Bjo¨rn Olsen and Naomi Fukai for
providing Col18a1/ mice.References
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